Episode #1
Listen to the first bankruptcy court hearing of defense contractor Noble Supply & Logistics held September 1, 2026
Sep 10, 202653 minS10
Loading…
Loading…
news
Hosted by Center of Main Interests · news · EN · 281 episodes
Audio recordings of American court proceedings
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
36%
Guest openness
Selective
Sign up to generate a grounded pitch for International Bankruptcy, Restructuring, True Crime and Appeals - Court Audio Recording Podcast.
Signup to Generate a PitchInternational Bankruptcy, Restructuring, True Crime and Appeals - Court Audio Recording Podcast is a news podcast hosted by Center of Main Interests, with 281 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.
Center of Main Interests hosts International Bankruptcy, Restructuring, True Crime and Appeals - Court Audio Recording Podcast, a news show with 281 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #1
International Bankruptcy, Restructuring, True Crime and Appeals - Court Audio Recording Podcast
For more information about the bankruptcy cases see https://cases.stretto.com/SVM/ (Bankruptcy Case Numbers and Bankruptcy Debtor Names): 26-10966 Searles Valley Minerals Inc. 26-10967 Trona Railway Company LLC 26-10968 Searles Domestic Water Company LLC
International Bankruptcy, Restructuring, True Crime and Appeals - Court Audio Recording Podcast
Per BioXcel's press release: BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals Aug 28, 2026 PDF Version BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH (“Teva”), a subsidiary of Teva Pharmaceutical Industries Ltd., for substantially all of the Company’s assets. This includes IGALMI® (dexmedetomidine) sublingual film and the related pending supplemental New Drug Application of BXCL501 for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Concurrent with the execution of the asset sale agreement, BioXcel Therapeutics and its subsidiaries, OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC, have commenced voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware (the “Court”) to facilitate a court-supervised sale process, which is expected to include the auction of substantially all of the Company’s assets. To anchor the sale process, Teva will serve as the sole “stalking horse bidder” for the sale of the assets contemplated by the asset sale agreement. A stalking horse asset sale agreement establishes a strong baseline offer and is intended to help maximize value for all stakeholders through the Chapter 11 auction process. “Following a comprehensive review of strategic alternatives, we believe this option provides a clear framework to pursue a value-maximizing transaction” said Vimal Mehta, Ph.D., Chief Executive Officer of BioXcel Therapeutics. “Our priority is to execute a disciplined and efficient sale process while supporting all of our stakeholders and continuing to support the sNDA with a PDUFA date of November 14, 2026. We are pleased to have a signed agreement with a leading pharmaceutical company to serve as stalking horse bidder in the process, underscoring the strategic interest in our assets and in IGALMI®....” For the rest of the BioXcel press release see: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-enters-asset-sale-agreement-teva For more information about the BioXcel bankruptcy/sale including the bankruptcy petitions and information about company assets and liabilities see: https://cases.stretto.com/bioxcel/ Typically, in situations such as these, there is a proposed buyer referred to as a stalking horse, and there is also an opportunity for other parties to come forward and bid on the assets.
International Bankruptcy, Restructuring, True Crime and Appeals - Court Audio Recording Podcast
International Bankruptcy, Restructuring, True Crime and Appeals - Court Audio Recording Podcast
This is the argument to the US Court of Appeals for the DC Circuit, released to the court's website June 8, 2026. The argument opens with an interesting discussion of standing that the Supreme Court might consider on appeal. Status as of today, August 25, 2026, is the US Supreme Court has entered a stay, allowing construction to continue for now. https://www.scotusblog.com/2026/08/supreme-court-allows-white-house-ballroom-construction-to-continue-for-now/
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
